Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed - 2Von der Leyen: Paris meeting sends signal of unity for Ukraine
- 3Building an Individual Brand: Illustrations from Forces to be reckoned with
- 4US bishops officially ban gender-affirming care at Catholic hospitals
- 5How to Build a Yard That Helps Monarchs During Spring Migration
- 5 VIP Voice Exhibitions in Energized Movies
- Share your pick for the riding area that characterizes your surf undertakings!
- Inconceivable Spots To Stargaze All over The Planet
- Chinese astronauts’ return to Earth delayed over fears spaceship damaged by debris
- Golden Globes 2026 full nominations list: 'One Battle After Another' and 'The White Lotus' lead in film and television categories
- California is completely free of drought for the first time in 25 years
- 6 Top Computer game Control center
- The Way to Monetary Health: Individual budget Change
- Nurturing Hacks: Shrewdness from Experienced Mothers and Fathers
